PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
29620694-3	2018	The aim of this study was to determine whether genetic variations in the genes encoding muscarinic and serotonergic receptors (CHRM2, CHRM3, HTR2, HTR3, HTR4, and HTR7) explain the variations in incidence of constipation and anticholinergic symptoms during clozapine treatment.	Clozapine	257-266	5-hydroxytryptamine receptor 3A	Homo sapiens	147-151	
20168265-2	2010	In this study, we further investigated the role of the subunits A and B of the HTR3 receptor using 140 schizophrenia patients taking clozapine for 6 months.	Clozapine	133-142	5-hydroxytryptamine receptor 3A	Homo sapiens	79-83	
22700043-0	2012	Outcome definitions and clinical predictors influence pharmacogenetic associations between HTR3A gene polymorphisms and response to clozapine in patients with schizophrenia.	Clozapine	132-141	5-hydroxytryptamine receptor 3A	Homo sapiens	91-96	
22700043-3	2012	Functionally important HTR3A gene single-nucleotide polymorphisms (SNPs) were reported to be associated with response to clozapine.	Clozapine	121-130	5-hydroxytryptamine receptor 3A	Homo sapiens	23-28	
22700043-4	2012	OBJECTIVE: The aim of this study was to investigate how the association between HTR3A gene SNP and response to clozapine is influenced by various clinical predictors and by differing outcome definitions in patients with treatment-resistant schizophrenia (TRS).	Clozapine	111-120	5-hydroxytryptamine receptor 3A	Homo sapiens	80-85	
12363396-8	2002	These results make unlikely the possibility that 5-HT3A and 5-HT3B receptor genes underlie variation in clinical response to clozapine.	Clozapine	125-134	5-hydroxytryptamine receptor 3A	Homo sapiens	49-55